• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma
The COhort of BRonchial obstruction and Asthma (COBRA) is a longitudinal cohort that involves 12 French academic institutions. DNA, serum samples and clinical data are collected at entry and every 6 months thereafter. Of 1080 patients with asthma recruited between 2007 and 2015, 401 had mild/moderate and 613 had severe asthma. In cross-sectional analyses, compared with patients with milder disease, patients with severe asthma had more symptoms, exacerbations, hospitalisations and visits to the emergency department during the preceding 12 months, higher numbers of blood eosinophils, and more comorbidities. More th...
Source: European Respiratory Journal - August 24, 2017 Category: Respiratory Medicine Authors: Pretolani, M., Soussan, D., Poirier, I., Thabut, G., Aubier, M., on behalf of the COBRA Study Group Tags: Asthma and allergy Original Articles: Asthma Source Type: research

Real-life Efficacy of Omalizumab After 9 Years of Follow-up.
Authors: Menzella F, Galeone C, Formisano D, Castagnetti C, Ruggiero P, Simonazzi A, Zucchi L Abstract Omalizumab is frequently used as add-on treatment to inhaled corticosteroids (ICS) and long-acting β2-agonists in patients with suboptimal control of severe asthma. Patients with severe asthma will typically require chronic treatment, although due to the limited amount of data available there are still some concerns about the safety and efficacy of long-term therapy with omalizumab. Herein, in an extension of a previous 4-year study, we report disease-related outcomes of 8 patients with severe persistent allergic...
Source: Allergy, Asthma and Immunology Research - May 13, 2017 Category: Allergy & Immunology Tags: Allergy Asthma Immunol Res Source Type: research

Real ‐life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria
Conclusions & RelevancePatients with severe allergic asthma above recommended dosing criteria for omalizumab have significantly improved symptom control, quality of life, and lung function to a similar degree to within‐range participants, achieved without dose escalation above 750 mg.This article is protected by copyright. All rights reserved.
Source: Clinical and Experimental Allergy - July 4, 2016 Category: Allergy & Immunology Authors: Mark Hew, Andrew Gillman, Michael Sutherland, Peter Wark, Jeff Bowden, Michael Guo, Helen K Reddel, Christine Jenkins, Guy B. Marks, Frank Thien, Janet Rimmer, Gregory P Katsoulotos, Matthew Cook, Ian Yang, Constance Katelaris, Simon Bowler, David Langton Tags: Original Article ‐Asthma and Rhinitis Source Type: research

Real‐life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria
Conclusions & RelevancePatients with severe allergic asthma above recommended dosing criteria for omalizumab have significantly improved symptom control, quality of life, and lung function to a similar degree to within‐range participants, achieved without dose escalation above 750 mg.This article is protected by copyright. All rights reserved.
Source: Clinical and Experimental Allergy - June 30, 2016 Category: Allergy & Immunology Authors: Mark Hew, Andrew Gillman, Michael Sutherland, Peter Wark, Jeff Bowden, Michael Guo, Helen K Reddel, Christine Jenkins, Guy B. Marks, Frank Thien, Janet Rimmer, Gregory P Katsoulotos, Matthew Cook, Ian Yang, Constance Katelaris, Simon Bowler, David Langton Tags: Original Article ‐Asthma and Rhinitis Source Type: research